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Bidirectional interactions between dendritic cells and Ag-experienced T cells initiate 
either a tolerogenic or immunogenic pathway. The outcome of these interactions is of 
crucial importance in malignancy, transplantation, and autoimmune diseases. Blockade 
of costimulation results in the induction of T helper cell anergy and subsequent dif-
ferentiation of antigen-specific CD8+ T suppressor/regulatory cells (Ts). Ts, primed in 
the presence of inhibitory signals, exert their inhibitory function in an antigen-specific 
manner, a feature with tremendous clinical potential. In transplantation or autoimmunity, 
antigen-specific Ts can enforce tolerance to auto- or allo-antigens, while otherwise leav-
ing the immune response to pathogens uninhibited. Alternatively, blockade of inhibitory 
receptors results in the generation of cytolytic CD8+ T cells, which is vital toward defense 
against tumors and viral diseases. Because CD8+ T cells are MHC Class I restricted, they 
are able to recognize HLA-bound antigenic peptides presented not only by APC but also 
on parenchymal cells, thus eliciting or suppressing auto- or allo-immune reactions.
Keywords: CD8+ T suppressor cells, iLT3, co-stimulation blockade, transplantation, autoimmune disease, gene 
profile of CD8+ Ts
iNTRODUCTiON
Over the last decade, the prevailing dogma has been that self-tolerance is mediated through domi-
nant suppression of autoimmune responses by regulatory CD4+CD25+FoxP3+ T cells (CD4+ Treg). 
Naturally occurring Tregs specifically express the transcription factor FOXP3 (forkhead box P3) (1). 
Natural CD4+CD25+ Treg constitute 5–10% of peripheral CD4+ T cells in normal mice and <5% in 
humans. Their essential role in tolerance was shown by experiments in which the depletion of natural 
Tregs from the thymus of newborn rodents resulted in enhanced immune responses to conventional 
bacteria from the intestine. This provoked inflammatory bowel disease (IBD) and the development 
of autoimmune diseases. In contrast, expansion of Tregs suppressed allergy, organ allograft rejec-
tion, graft-versus-host disease after bone marrow transplantation, and various autoimmune diseases 
(1–5).
The revival of CD8+ suppressor cells (CD8+ Ts) after decades of deliberate omission has been well 
described in some review articles (6–8). The function of CD8+ Ts was first documented in the early 
80s by Gershon et al. (9). With the advent of molecular immunology, the existence of the murine I-J 
locus, presumed to encode Ts function, could not be confirmed. For fear of rejection and denial of 
grant support, the word “suppressor” was arbitrarily replaced with that of “regulatory” T cells, even 
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though the sole function of regulators was to suppress immune 
function. For this reason, the reader of the suppressor literature 
would be well advised to search the listing of papers referring to 
either CD8+ Treg or T suppressor cells (CD8+ Ts).
Both CD8+ and CD4+ Tregs showed similar expression levels 
of FOXP3 and CTLA-4, which represent their most characteristic 
markers. On the other hand, the biggest difference between CD4+ 
and CD8+ Tregs resides in the expression of CD28 (10). CD4+ 
Tregs express a higher level of CD28, which is required for their 
interaction with B7 molecules. B7 molecules regulate thymic 
development and peripheral tolerance (11). For CD8+ T cells, the 
expression of CD28 is partially dispensable due to their reduced 
production of IL-2 (12–14).
NATURAL AND NON-ANTiGeN-SPeCiFiC 
CD8+ Treg
Similar to natural CD4+ Treg, CD8+ thymus-derived natural 
Tregs have also been described. Characteristically, these cells 
have a CD28− phenotype in both mice and human (15). However, 
after TCR triggering, both CD4+ and CD8+ natural Treg inhibit 
the immune response in an antigen non-specific and MHC 
non-restricted manner via direct interaction between Treg and 
activated T cells. Naturally occurring CD8+ Treg were reported 
to have a CD8+CD25+CTLA-4+GITR+FoxP3+ phenotype and 
suppress in a CTLA-4- and TGF-β1-dependent manner (16).
The Qa-1-restricted CD8 alpha, alpha+ (TCR alpha beta+), 
population is the best characterized population of CD8+ natural 
Treg in mice. The Qa-1 molecule (homolog of HLA-E in human) 
presents peptides derived from the non-hypervariable domain of 
the TCR. These Vbeta-specific CD8+ Tregs interact and inhibit 
the activation of CD4+ T cells with similar Vbeta regardless of 
their specificity (17–20).
Study of the miRNA profile of human CD8+CD25+ natural 
Treg revealed 10 differentially expressed miRNAs (miR-214, 
-205, -509 overexpressed and miR-9, -24, -31, -155, -335, -210, 
and -449 under expressed), which seem to display specific regula-
tion of FOXP3, CTLA-4, and GARP gene expression (21).
Peripheral CD8+ CD28− Foxp3− CD56− non-antigen-specific 
Ts were reported to be easily generated and expanded by cultur-
ing CD8+CD28− T cells in a cocktail of cytokines containing 
IL-2, IL-10, and GM-CSF. They were expanded without antigenic 
stimulation and seemed to inhibit antigen recognition, T cell 
proliferation, and cytotoxicity via IL-10 secretion (22, 23). It has 
been suggested that such Ts can be extracted from patients during 
disease remission and reinfused during disease exacerbation (24).
ADAPTive ANTiGeN-SPeCiFiC  
CD8+ Treg
Adaptive CD8+ Ts originate from the post-thymic T cell pool and 
are induced by a variety of in vivo and in vitro antigenic stimuli. 
Antigen-specific Treg are required for efficient suppression of 
T cell immune responses against MHC-bound peptides derived 
from auto- or allo-antigens. The best characterized Treg in this 
category include human CD8+CD28−, MHC class I-restricted, 
T suppressor, and CD4+CD25+CD45RO+, MHC class II-restricted, 
Treg cells (10). Our previous studies have demonstrated that MHC 
allo-restricted CD8+CD28− Ts can be generated in vitro by multi-
ple rounds of T cell stimulation in the presence of allogenic APC. 
Evidence has been provided that Ts develop in vivo from rejection-
free organ allograft recipients. Antigen-specific CD8+CD28− Ts 
exert their function by conditioning APC to become tolerogenic. 
Our studies on the mechanism of CD8+CD28− Ts-mediated sup-
pression revealed that they act via an APC bridge, inducing the 
upregulation of immunoglobulin-like transcript (ILT) inhibitory 
receptors on professional (dendritic cell and monocytes) as well 
as on non-professional [endothelial cells (EC)] APC (25–29).
CD8+ Ts AND iLT3
The induction of tolerogenic dendritic cells (DCs) was first 
established in 1998 by our group (26). We showed that human 
CD8+CD28− Ts cells generated by multiple rounds of in vitro allo-
stimulation interact with APC, inducing the downregulation of 
co-stimulatory molecules and thereby reducing their capacity to 
trigger CD4+ T helper (Th) cell activation (27). In the absence of 
Th cell help, CD8+ T cells from the same culture acquire suppres-
sor activity. Similarly, multiple stimulations of human T cells with 
xenogeneic APC or with peptide-pulsed autologous APC resulted 
in the generation of antigen-specific CD8+CD28− Ts cells (28, 29). 
These CD8+ Ts cells, derived from an oligoclonal population, are 
MHC class I restricted and express same levels of FOXP3, GITR, 
CTLA-4, CD25, OX40, CD103, CD62L, 4-1BB, and TNFRII as 
seen in CD4+CD25+ natural T regulatory (Treg) cells (10, 30).
CD8+CD28− Ts can be distinguished from CD8+CD28− CTL 
cells from the same multiple allo-stimulated T cell line (TCL) by 
the higher expression of some genes from the killer cell inhibitory 
receptor (KIR) family, such as KIR3DL1, KIR3DL2, and KIR2DL3 
and by their gene profile (10).
Upon restimulation with priming APC, CD8+ Ts do not 
produce IFN-γ, IL-10, TGF-β, or other cytokines. Instead, 
CD8+CD28− Ts inhibit CD40-mediated upregulation of co-
stimulatory molecules, such as CD80 and CD86 on priming 
APC, which become tolerogenic, upregulating the expression 
of the inhibitory receptors ILT3 (also called LILRB4, CD85K, 
or LIR5) and ILT4 (also known as LIR-2, LILRB2, or CD85d). 
Consequently, APC are rendered unable to induce and sustain 
the full program of CD4+ Th cell activation and maturation, due 
at least in part to inhibition of Nuclear Factor-κB (NF-κB) activa-
tion and subsequent transcription of co-stimulatory molecules 
(10, 26–29, 31–34).
Tolerogenic APC can be also generated by exposure of DC to 
IL-10, IFN-α, or IFN-β, which induce upregulation of ILT3 and 
ILT4 (14–17, 31–34).
The crucial role of ILT3 and ILT4 was revealed in experiments 
in which the myelomonocytic cell line KG1 was transfected with 
ILT3 or ILT4 and used for T cell allo-stimulation. Wild KG1 cells 
induced strong MLC responses, while ILT3- or ILT4-transfected 
KG1 cells were non-stimulatory. CD8+CD28− T cells from the 
same cultures inhibited autologous T cell responses to wild 
KG1 stimulating cells, displaying suppressor function. CD4+ 
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Th reactivity to KG1-ILT3 or KG1-ILT4 transfectants could be 
restored by adding to the cultures either anti-ILT3 or ILT4 mAb, 
respectively, or IL-2. These results indicated that ILT3- or ILT4-
expressing APC induce T cell anergy and elicit the differentiation 
of CD8+CD28− Ts (26).
Allogeneic CD40L-activated pDC (expressing high levels of 
ILT3 and ILT4) promote the differentiation of naïve CD8 T cells 
into CD8+ Ts. These CD8+ Ts inhibit T cell proliferation via secre-
tion of IL-10 (35).
While overexpression of ILT3 was shown to be a marker of 
tolerogenicity, knock down of ILT3 augmented the immunogenic 
capacity of activated DC, significantly increasing their capacity 
to migrate, produce inflammatory cytokines, and activate IFN-
γ- and IL-17-secreting T effector cells (36).
ILT3 and ILT4 belong to a family of Ig-like inhibitory receptors 
that are structurally and functionally related to KIRs. Some ILT 
family members, including ILT2, ILT3, and ILT4, have long cyto-
plasmic tails containing ITIM. These receptors mediate inhibition 
of cell activation by recruiting the tyrosine phosphatase SHP-1 
(37–40). Coligation of ILT3 and ILT4 in monocytes inhibits Ca2+ 
mobilization and tyrosine phosphorylation, which is triggered by 
Ab ligation of FcRII (CD32), HLA-DR, and FcγRI (CD64). The 
ligand for ILT3 has not been described so far. ILT4 was shown to 
bind to the α3 domain of HLA class I (HLA-A, HLA-B, HLA-C, 
and HLA-G), competing with CD8 for MHC class I binding (41, 
42). As a result, recombinant soluble ILT4 restores, rather than 
inhibits, Treg proliferation (43).
Besides the negative signaling that ILT3 transmits endog-
enously upon ligation, ILT3’s extracellular Ig-like domains are 
also endowed with inhibitory function. This was demonstrated in 
experiments for which we first engineered the myelomonocytic 
KG1 cell line (KG1-Delta) to overexpress a signaling-defective 
ILT3 deletion mutant which lacked the cytoplasmic tail contain-
ing ITIM. CD4+ T-cell responses in primary and secondary MLC 
were greatly deficient upon stimulation with these cells, which 
elicited instead the generation of CD8+CD28− Ts cells. This result 
suggested that the extracellular domain of ILT3 by itself carries 
out a tolerogenic function which is independent of the inhibitory 
intracellular signaling (43). Based on these findings, we engi-
neered a recombinant ILT3.Fc protein, which lacked both the 
trans-membrane and intracellular domain. When ILT3.Fc was 
added to T cells at the time of MLC priming, it suppressed CD4+ 
Th cell proliferation and elicited the differentiation of allospecific 
CD8+ Ts in vitro as well as in vivo. Hence, both membrane and 
soluble ILT3 induce CD4+ T helper anergy, triggering the genera-
tion of CD8+ Ts cells (41, 44, 45). This indicates that ILT3 is an 
essential immune checkpoint or master switch which regulates 
the outcome of the immune response.
Soluble ILT3, engineered as an ILT3.Fc fusion protein, was 
shown to induce tolerance to allogeneic human pancreatic islet 
transplants in humanized NOD/SCID mice (hu-NOD/SCID) 
(44) and to reverse progression of rejection after its onset (34). 
ILT3.Fc inhibited both the cellular and humoral arm of rejec-
tion, as shown by the inhibition of Th1 and Th2 proliferation and 
cytokine production, CTL generation, and synthesis of anti-HLA 
and xenospecific antibodies by B cells from tolerant animals (34, 
44, 46).
GeNe PROFiLe OF iLT3.Fc-iNDUCeD 
CD8+ Ts
ILT3.Fc dramatically changes the landscape of the gene expression 
profile in CD8+ Ts cells. Numerous genes in the WNT receptor 
pathway were significantly upregulated, indicating its impor-
tant role in the generation of CD8+ Ts cells. This data support 
the concept that activation of the WNT pathway inhibits CD8 
T-cell proliferation and cytotoxic effector cell differentiation. The 
expression of TGF-β and TGFBR2 was also significantly increased, 
consistent with the well-characterized cross talk between TGF-β 
and WNT pathway (47, 48).
ILT3.Fc extensively downregulated the expression of cyclins 
and cyclin kinases while upregulating cyclin-dependent kinase 
inhibitors. Considering the fact that cyclins and cyclin kinase 
together with their specific inhibitors are the most important 
positive and negative regulators in the cell cycle, it is reasonable 
to assume that ILT3.Fc induces cell cycle arrest, inhibiting T cell 
proliferation (47, 49).
On the gene transcriptional level, ILT3.Fc promotes the 
expression of transcriptional repressors which block the synthesis 
of cytokines and other factors necessary for T cell proliferation 
and differentiation. The zinc finger transcriptional repressor 
BCL6 is one of the genes whose elevated expression is important 
for the differentiation of ILT3.Fc-induced Ts. We found that 
transfection of BCL6 in allo-activated CD8+ T cells converted 
them into suppressors, whereas silencing of BCL6 in unprimed 
T cells prevented their differentiation into Ts when allo-stimulated 
in the presence of ILT3.Fc. BCL6-transfected Ts share highly 
similar characteristics with ILT3.Fc-induced Ts both in vitro and 
in vivo. The in vivo evidence is based on the finding that BCL6 
was overexpressed in human CD8+ T cells from humanized mice 
rendered tolerant to pancreatic islet transplants by treatment with 
ILT3.Fc (34). ILT3.Fc-induced repression of granzyme B, IFN-γ, 
IL-5, and enhancement of CXCR4 occurred in conjunction with 
the upregulation of BCL6 expression in CD8+ Ts cells. Hence, 
ILT3.Fc may arbitrate T cell lineage fate through BCL6-mediated 
repression of Th1, Th2, Th17, and CTL and induction of Ts dif-
ferentiation (34).
MiRNA represents a group of novel regulatory molecules 
which modulate gene function at the posttranscriptional level. 
Studies on the miRNA expression profile in ILT3.Fc-induced 
CD8+ Ts indicate that they also play a role in the generation of 
CD8+ Ts cells. ILT3.Fc inhibited the expression of miR-21, miR-
30b, and miR-155. Those miRNAs target the 3′-untranslated 
region of DUSP10, BCL6, and SOCS1, genes whose transcription 
was highly increased in ILT3.Fc-induced Ts.
Primed CD8+ T cells transfected with miR-21 and 30b, miR-21 
and 155, or miR-21, 30b, and 155 inhibitors displayed suppressor 
activity when added to autologous CD3-triggered CD4+ T cells. 
Luciferase reporter assays of miR-21 and miR-155 indicated that 
their transcription is highly AP1 dependent, consistent with the 
finding that for the AP1 subunits, FOSB, and c-FOS, transloca-
tion to the nucleus is inhibited by ILT3.Fc. In summary, ILT3.
Fc inhibits T cell activation and induces the generation of Ts by 
targeting multiple inflammatory miRNA pathways (50). Recent 
studies on human natural CD8+CD25+FOXP3+CTLA-4+ Treg 
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cells revealed similar miRNA signatures. The data indicate that 
miRNAs, including miR-9, -24, -155, and -335, play an important 
role in the induction of CD8+ Treg by modulating Treg-associated 
genes (21).
Studies of exosomes from MLC supernatants revealed the 
presence of inflammatory microRNA, including miR-146a, 
miR-155, miR-21, miR-30b, miR-365, and Let-7a. These miR-
NAs were inhibited when ILT3.Fc was added to the culture, 
they were produced exclusively by CD4+ T cells, being absent 
from CD4-depleated cultures. Furthermore, upon treatment 
with exosomes containing inflammatory microRNA, ILT3.
Fc-induced CD8+ Ts lost their suppressive activity at low Ts/T 
effector cell ratio (51).
MiRNAs contained by exosomes released from allo-activated 
T cells enhanced T helper activity even in the presence of limit-
ing amounts of allospecific T suppressor cells. This suggests that 
increased amounts of microRNA in recipients’ sera may serve as 
markers of active immune responses against the graft, even in the 
presence of regulatory T cells. Furthermore, such exosomes may 
be of use in eradicating tumors in patients developing lymphoid 
malignancies secondary to immunosuppression and viral (EBV, 
CMV, Hepatitis B and C) infections (51).
Comparison of ILT3.Fc-induced CD8+ Ts with CD8+CD28− Ts 
induced in MLC by chronic allogenic stimulation demonstrated 
that the characteristic signatures of CD8+ T suppressor cells 
generated by either of these methods are the same, consisting 
of upregulation of the BCL6 transcriptional repressor and 
downregulation of inflammatory microRNAs, miR-21, miR-30b, 
miR-146a, and miR-155. In conclusion, microRNAs, which are 
increased under inflammatory conditions in activated CD4+ and 
CD8+ T cells with helper or cytotoxic function, show low levels 
of expression in CD8+ T cells that have acquired antigen-specific 
suppressor activity (52).
CD8+ Ts iN TRANSPLANTATiON
The possible role of ILT3 and ILT4 molecules in maintenance of 
quiescence in transplant patients is of obvious interest. We found 
that T cells from heart and liver transplant patients in quiescence, 
but not from recipients with a history of rejection episodes, 
induced the upregulation of ILT3 and ILT4 and downregulation 
of CD80 and CD86 in cryopreserved APC from the donor. As a 
surrogate for donor APC, DC matched to the donor for at least 
one HLA class I and one HLA Class II (DR) can be used for flow 
cytometry and functional assays.
Monitoring of kidney allograft recipients who have been 
chronically exposed to rapamycin showed increased numbers 
of DC with the ILT3+ILT4+ tolerogenic phenotype and of T 
cells with the CD8+CD28− suppressor phenotype suggesting 
that mTOR inhibition promotes a novel immunoregulatory 
pathway (53).
However, since donor DC migrate out of the graft early fol-
lowing transplantation, it was still unclear how quiescence was 
maintained by some, but not all organ allograft recipients. The 
most likely explanation seems to be that graft EC, which are 
non-professional APC that express all donor HLA allo-antigens, 
become tolerogenic. To explore the possibility that EC are targeted 
by recipient CD8+CD28− Ts, we transfected umbilical cord EC 
(matched to the donor for at least one HLA class I antigen) with 
luciferase ILT3 or ILT4 reporter gene and performed luciferase 
transcription assay in the presence of recipient CD8+CD28−  
T cells. These experiments demonstrated that CD8+CD28−FoxP3+ 
T cells from the circulation of rejection-free heart transplant 
patients triggered the expression of ILT3 and ILT4 in EC-sharing 
class I HLA antigens with the graft. CD8+ T cells from patients 
with recurrent episodes of acute or with chronic heart allograft 
rejection did not display ILT3-inducing capacity (54, 55). Using 
cell fractionation and sequencing studies, we further showed that 
ILT3 precursor RNA are expressed and retained in the nuclei of 
resting EC. Ts interaction with EC or exposure of EC to IL-10 
and IFN-α triggers processing of ILT3 pre-mRNA. Western blot 
analysis showed that the expression of the mature ILT3 transcript 
is accompanied by production of ILT3 protein (56). Studies from 
other laboratories further confirmed our finding that IL-10 
also inhibits endothelium-dependent T cell co-stimulation by 
upregulating ILT3 and ILT4 in human vascular EC (57).
The tolerogenic role of EC, which express inhibitory molecules, 
was further explored in a Lewis to ACI rat heart transplantation 
model. After three injections of UV-irradiated blood from Lewis 
donors, about 50% of the ACI recipients became tolerant to 
donor strain heart transplants. Tolerance could be transferred 
to secondary ACI recipients by CD8+ but not by CD4+ T cells. 
Furthermore, the graft of these secondary recipients was tolerated 
indefinitely even when transplanted to tertiary, non-conditioned 
ACI recipients. The CD8+ T cells used for adoptive transfer of 
tolerance were FoxP3+. They induced the expression of PIR-B, 
a rat ortholog of ILT4, not only in donor APC, but also in the 
EC lining the aorta of the transplanted heart. Hence, this phe-
nomenon of “graft adaptation” was mediated by the induction of 
inhibitory receptors in graft EC by MHC Class I allo-restricted 
CD8+ suppressor cells (58).
Recently, it was shown that kidney–pancreas transplantation 
in a type I diabetic patient was characterized by an increased 
presence of CD8+CD28− Treg in the pancreas and elevated levels 
of ILT3 expression on APC in a donor-specific manner (59).
Our conclusion that generation of allospecific CD8+CD28− Ts 
may require the induction of anergy in CD4+ T helper cells (Th), 
e.g., leaving the primed CD8+ T cells “helpless,” is supported by 
other groups. These investigators used the same MLC stimulation 
model, but “allo-anergized” Th by adding to the MLC a CTLA-4 
immunoglobulin fusion molecule (Belatacept) which blocks the 
CD28-B7 co-stimulation pathway. They further confirmed our 
finding that repeated rounds of allo-stimulation results in relative 
and absolute expansion of CD8+Foxp3+ Ts. Finally, they found 
that allo-anergized CD8+CD28− Ts of donor origin are expanded 
in recipients of allogeneic hematopoietic stem cell transplantation 
(60). This finding is reminiscent of our and other authors’ previ-
ous observation that CD8+CD28− Ts are present in the circulation 
of transplant recipients in quiescence (26, 61–63).
Human allo-antigen-specific CD8+ Tregs were generated in a 
large scale from antigenically naïve precursors by in vitro stimula-
tion with allogeneic CD40 activated B cells. These cells inhibited 
GVHD in a humanized mice model, suppressing allo-reactive 
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T cell proliferation and cytokine production by a CTLA-4-
dependent mechanism (64). In other studies, CD8+CD28−Tregs 
were generated in MLC by coculture with mesenchymal stem 
cells, a method of potential use given the resistance of CD28− T 
cells to treatment with Belatacept, an agent which blocks CD28/
B7 co-stimulation, preventing alloreactivity in kidney transplant 
recipients (65).
In recent studies, CD8+CD28− Ts cells were generated by 
multiple MLC simulation and expanded by adding common 
gamma chain cytokines IL-2, IL-7, and IL-15 to the cultures. The 
expanded population exhibited increased expression of CTLA-4, 
FOXP3, and CD25, while the expression of CD56, CD57, CD127, 
and perforin was downregulated (66). Consistent with our own 
studies, suppression of CD4 Th by CD8+CD28− Ts was HLA class I 
allo-restricted and cytokine independent. However, the claim that 
after expansion these cells keep their suppressor function without 
killing the stimulating APC, as demonstrated in CFSE cytotoxic 
assays, could not be confirmed in our own studies for which the 
traditional Cr-51 release from target cells was used. We found that 
when these cytokines were used for expansion, the proliferating 
population consisted of CD8+ CTL. It is apparent that rather than 
being in a terminal stage of differentiation, CD8+CD28− Tcells 
can be expanded indefinitely given the appropriate mixture of 
cytokines (67). A similar phenomenon has been described for 
CD4+. Zhou et  al. have shown that CD4+ Tregs constitute an 
unstable T cell subset that can be reprogramed into pathogenic 
effector cytokine-producing T cells. Such CD4+ T cells down-
regulate their FOXP3 expression, losing suppressive capacity and 
acquiring an activated-memory phenotype (68). These findings 
reflect the plasticity of both CD8+ and CD4+ Treg cells, which 
can revert their function from suppressors to effector cells. 
A comprehensive review of CD8+ Treg in animal transplantation 
studies can be found in Guillonneau et al., which also emphasizes 
the identification of PD-1 as a marker of CD8+ Ts in rodents (69).
Recently, a new subset of CD8+CD122+PD1+ Tregs, which 
produce IL-10, IFN-γ, and TGF-β and suppress CD4+ T cell 
activation, has been described in mice. Its counterpart in human 
is still unknown (70). This CD8+cd122+ Treg subset was claimed 
to more potently suppress allograft rejection compared to their 
CD4+CD25+ Tregs (71). Therefore, it appears that CD8+CD28−, 
CD8+Qa-1+, CD8+CD103+, and CD8+CD122+PD-1+ Treg sub-
sets may share the capacity of maintaining homeostasis with an 
equally heterogeneous population of CD4+ Tregs.
CD8+ Ts CeLLS iN AUTOiMMUNe 
DiSeASeS
CD8+ T cells can oppose or promote autoimmune disease through 
activities as suppressor or as cytotoxic effectors (72). Data have 
been presented that CD8+CD28−CD56− T cells have suppressive 
activity in rheumatoid arthritis (RA), preventing the activation 
of naïve CD4+ T cells and inhibiting their effector function 
in vivo. When transferred into NOD-SCID chimeras engrafted 
with human synovial tissue, they suppressed the inflammatory 
activity in the synovial lesions and inhibited cytokine production 
(73). Rheumatoid synovitis could also be treated in such chimeras 
by infusing autologous CD8+CD16+ T cells, which inhibits the 
production of IL-1β, IFN-γ, TNF-α, and other inflammatory 
cytokines. Treatment with IL-16 mimicked the effect of the 
adoptive transfer of Ts and anti-CD16 antibodies abrogated the 
suppressor effect (74). Similarly, there is evidence that CD8+ Ts 
generated from SLE patients during remission had suppressor 
activity, while CD8+ obtained during exacerbation of the disease 
had no such activity (75).
Glatiramer acetate (GA) introduced in the therapy of multiple 
sclerosis has been shown to induce CD8+ Ts, which seem to 
recognize GA on the cell surface and directly kill CD4+ T cells 
in a HLA-E-dependent manner (76). Ulcerative colitis and 
Crohn’s disease are other examples of pathological processes in 
which CD8+ Ts may inhibit proliferation of CD4+ T cell through 
a TGF-β-dependent mechanism (77). Intestinal epithelial cells 
may activate CD8+ Ts cells, which downregulate IBD, suppress-
ing IgG production (78). In JDM, a one-course administration 
of humanized anti-CD3 mAb was claimed to induce the genera-
tion of CD8+ CD25+CTLA-4+FoxP3+ Ts cell, which were able to 
inhibit the stimulation of CD4+ T cells in in vitro coculture system 
(79, 80). Accumulating evidence indicates that co-inhibitory 
molecules, such as CTLA-4, PD1, and BTLA, are negative regula-
tors of immune responses since deficiencies or mutations result 
in the development of autoimmune diseases. The administration 
of decoy co-inhibitory receptors, such as CTLA-4.Ig or agonistic 
antibodies, can suppress the response of self-reactive T cells in 
autoimmune diseases.
Abatacept, a fusion protein composed of the Fc fragment of 
human IgG1 linked to the extracellular domain of CTLA-4, has 
shown efficacy in a broad spectrum of RA patients from early 
stage to refractory diseases that are resistant to TNF blockers 
(81–84).
In addition, Abatacept showed efficacy in patients with juve-
nile idiopathic arthritis, psoriasis, and SLE. CTLA-4 competes 
with CD28 on the membrane of activated T cells for binding to B7 
molecules (CD80 and CD86) on APC, delivering negative signals 
which inhibit or terminate T cell responses.
PD1, another co-inhibitory receptor from the CD28 family, 
which is expressed on activated T cells (as well as on B cells and 
monocytes), binds to two ligands of the B7 family, PD-L1 and 
PD-L2. The ligation of PD-1 with these ligands inhibits CD4+ 
and CD8+ T cell proliferation by arresting the cell cycle (85–87). 
However, in human, PD1 ligation is important to inhibition 
of cell proliferation and death by apoptosis, rather than to the 
generation and function of CD8+ Ts.
BTLA-HVEM pathway is another inhibitory pathway for 
lymphocyte activation [reviewed in Ref. (78)]. BTLA4, a member 
of the TNF family, is expressed on CD4+ and CD8+ T cells, NK 
and NKT cells, as well as on B cells, DC, and macrophages. Its 
ligand HVEM is also widely expressed on hematopoietic cells, 
including T cells and APC. Ligation of BTLA induces its tyrosine 
phosphorylation and SHP-1/SHP-2 association, inhibiting T cell 
proliferation and IL-2 production. Deficiency of BTLA-HVEM 
interaction has been shown to be involved in autoimmune dis-
eases, though no clinical trial is yet in progress.
Although current methods of immunotherapy in cancer are 
largely based on the use of the immune checkpoint inhibitors 
anti-CTLA-4 and anti-PD-1 antibodies, the major obstacle 
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resides in opportunistic autoimmune disorders and associated 
morbidity resulting from altered immune regulation (88, 89).
Other lymphocyte subsets believed to have suppressor 
function in autoimmune diseases and transplantation include 
CD3+CD4−CD8− (double negative Treg), CD4+, Valpha14 nega-
tive (NKTreg), and gamma/delta Treg cells. It was postulated that 
there are four modes of Treg function: (1) secretion of inhibitory 
cytokines such as IL-10 and TGF-β; (2) granzyme-perforin-
induced apoptosis of effector T lymphocytes; (3) induction of 
apoptosis by deprivation of cytokines; and (4) inhibition of DC 
function (8, 90).
Specific recognition of the MHC Class Ib Qa-1bound peptides 
expressed on activated CD4 T cells by regulatory, cytolytic CD8+ 
T cells was postulated to prevent autoimmunity in mice (91). 
A similar function has been attributed to human neuroantigen-
specific CD8+ Treg, which recognize HLA-E-bound peptides 
and are present in the circulation of patients with multiple 
sclerosis (92).
A distinct subset of human CD8+CD25+FoxP3+ Treg seems to 
be characterized by the expression of the lymphocyte activation 
gene-3 (LAG-3). The suppressive activity of this subset has been 
attributed to the secretion of the CC chemokine ligand 4 (CCL4), 
which interferes with TCR signaling, inhibiting T cell activation. 
These Tregs can be expanded only from T cells primed in vivo to 
a specific antigen by repeated or chronic stimulation in vitro or 
in vivo, respectively. This indicates that they are adaptive Treg (90).
It has been shown that autologous hematopoietic stem cell 
transplantation in refractory SLE can induce immunological 
tolerance to auto-epitopes from nucleosomes by restoring the 
CD8+FoxP3+ TGF-β producing pool of suppressors. These Ts 
maintained high expression levels of latency-associated peptide 
(LAP), CD103, PD-L1, and CTLA-4 following transplantation 
and completely inhibited autoimmunity (93).
Collectively these data indicate the importance of CD8+ Treg 
in suppressing autoimmune responses and transplant rejection.
CD8+ ReGULATORY T CeLLS iN 
PeRSiSTeNT viRAL iNFeCTiON
The control of virus-specific immune responses may be a mecha-
nism that permits virus persistence. On the other hand, it may 
also protect the patient from overwhelming T cell reactivity and 
destruction of infected tissues (94).
In patients with HIV, it was shown that stimulation of patients’ 
PBMC with HIV-specific antigens induced TGF-β-producing 
CD8+ Treg. These CD8+ Treg suppressed the IFN-γ production of 
HIV-specific and vaccinia virus-specific CD8+ T cells, displaying 
both a specific and non-specific activity. IL-10-producing CD8+ 
Treg were also expanded from the peripheral blood of HIV-
infected individuals and their frequency seems to be associated 
with impairment of CD8+ effector-cytolytic function (95–97).
Distinct populations of CD8+ Ts were also shown to be present 
in the blood and liver of patients with chronic HCV infection. 
Some investigators reported the expansion of CD25−FoxP3−CD8+ 
Treg that inhibited IFN-γ production of HCV-specific CD4+ and 
CD8+ T cells via TGF-β production. A population of HCV-specific 
FoxP3+CD8+ Treg was also expanded by stimulation with HCV 
peptides of PBMC from patients with chronic HCV infection. 
These cells inhibited in an antigen non-specific manner, T cell 
proliferation via direct T cell–T cell interaction (98, 99). Similarly, 
expansion of virus-specific CD8+BTLA+ T cells in the liver was 
observed in patients with chronic HBV infection. These infiltrat-
ing regulatory T cells were antigen specific and suppressed T cell 
responses via IL10 secretion (100).
Intra-hepatic IL-10-secreting CD8+ Treg were described to be 
present in patients with chronic infection and to suppress IFN-
production of effector CD8+ T cells primed to the same HCV 
peptide. Blockade of IL-10 restored effector activity (101).
Herpes viruses, such as EBV, CMV, or HSV, which infect many 
people worldwide, establish persistent latent infections which, 
upon reactivation in immunological deficient individuals, are 
responsible for life threatening episodes of infection. EBV-specific 
CD8+FoxP3+ Treg cells produce IFN-γ and IL-10 but not TGF-
β and suppress CD4+ T cell proliferation in a cell–cell contact 
manner. Similar mechanisms seem to occur in CMV infection 
(102, 103).
Evidence has been provided that dermal CD14+ DCs, which 
express ILT2 and ILT4, prime a fraction of naïve CD8+ T cells 
that produce type 2 cytokines (IL-4 and IL-5) as opposed to 
Langerhans cells, which have no ILTs and are highly efficient in 
priming CD8+ CTL. The ILT molecules on dermal DC polarized 
the T cell response toward type2 cytokine producers, as blocking 
of these receptors enhanced the generation of CTL (104).
Accumulating evidence revealed that viruses have evolved 
strategies to evade the immune surveillance by inducing specific 
Tregs. Novel strategy show promising antiviral effects by deletion 
or inactivation of viral-induced Tregs cells (105).
CONCLUSiON
In light of the multiple pathways which may lead to the activation, 
generation, and expansion of T cells with antigen-specific func-
tion, it is obvious that therapy based on enhancement or blockade 
of immune checkpoints used by T cells for interacting with other 
cells holds promising results. Recombinant ILT3.Fc, CTLA-4.
Ig, PD-L1.Ig, or humanized monoclonal antibodies which block 
effector–ligand interaction are only examples of the numerous 
agents that may have beneficial effects. However, the success of 
novel therapies aimed at suppression of autoimmune diseases 
depends on progress in certain areas:
 1. It is apparent that inhibition of immune responses to uniden-
tified autoantigens, deriving from a variety of tissues, calls 
for a better understanding of signaling pathways activated 
by ligation of different co-inhibitory checkpoints. This may 
allow for the design of combination therapy in which agents 
which act in synergy can be used to inhibit the activation and 
maturation of effector T helper and cytotoxic cells.
 2. Studies on mechanisms’ underlying memory of both effec-
tors and suppressors of T cell immune responses to defined 
antigens may permit the design of clinical protocols which 
maintain quiescence in patients in remission.
 3. Identification of markers that characterize different stages 
of T cell conversion from one effector function to another, 
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as exemplified by CD8+ suppressor and cytotoxic T cells, as 
well as of the mechanism of such a transition, is required for 
patients’ monitoring and better timing of therapy.
 4. Progress in understanding the way in which cells communi-
cate with each other to perceive endogenous and exogenous 
signals may open new horizons to immunotherapy of autoim-
mune diseases and of cancer.
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